Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10434746 | 0.81 | FAAH (0.56) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL13913531 | 0.79 | FAAH (0.54) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL20633412 | 0.79 | FAAH (0.54) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL3392525 | 0.79 | NAAA (0.74) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL11372041 | 0.79 | FAAH (0.64) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL11800753 | 0.79 | FAAH (0.54) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL18716598 | 0.79 | GAA (0.58) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL10434775 | 0.78 | — | — | |
| SCHEMBL11370007 | 0.78 | NAAA (0.77) | FAAHNAAAGAAHSD17B10NPSR1 | |
| SCHEMBL11191345 | 0.78 | NAAA (0.83) | FAAHNAAAGAAHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | claimed |
| CN-101268041-A | Sulphonamide derivatives | BIOTIE THERAPIES CORP (FI) | 2008-09-17 | — | — | CN | claimed |
| EP-1924554-A1 | SULPHONAMIDE DERIVATIVES | Biotie Therapies Corp. (FI) | 2008-05-28 | — | — | EP | claimed |
| WO-2007034035-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2007-03-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | HCAR1, ADGRE5, ALK | FAAH 656/4885NAAA 2395/4885GAA 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.